Metal complex of anthroyl thiosemicarbazone compound, and preparation and use thereof
By synthesizing anthraquinone thiohexacarbazone compounds and their metal complexes, the problem of poor efficacy of existing anthracycline drugs in treating drug-resistant tumors has been solved, achieving highly effective and low-toxicity anti-tumor treatment.
Patent Information
- Application Number
- PCT/CN2026/096361
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Existing anthracycline drugs are ineffective in treating drug-resistant tumors and have high toxicity and side effects. There is a need to develop new compounds to improve anti-tumor activity and reduce drug resistance.
Anthraylthio-semicarbazone compounds and their metal complexes were synthesized. By forming complexes with metal ions, their high antitumor activity and low drug resistance characteristics were utilized to prepare antitumor drugs.
It exhibits significant anti-tumor activity, demonstrates highly effective treatment against various drug-resistant tumor cells, and has low toxicity and low drug resistance index, thus overcoming the challenge of treating multidrug-resistant tumors.
Smart Images

Figure PCTCN2026096361-FTAPPB-I100001 
Figure PCTCN2026096361-FTAPPB-I100002 
Figure PCTCN2026096361-FTAPPB-I100003
Abstract
Description
Metal complexes of anthraylthiohexacarbazone compounds, their preparation and applications Technical Field
[0001] This invention belongs to the field of biomedicine, specifically, it relates to a class of anthraquinone thiosemicarbazone compounds as ligands, metal complexes thereof, their preparation and application. Background Technology
[0002] Anthracyclines are a class of chemotherapy drugs derived from *Streptomyces peucetins*. They can treat a wider range of cancers than any other type of chemotherapy drug, and chemotherapy using them is one of the most effective anti-cancer therapies currently available. Cancers they can treat include leukemia, lymphoma, breast cancer, uterine cancer, ovarian cancer, and lung cancer, demonstrating a very broad anti-tumor spectrum.
[0003] Due to the beneficial effects of anthracyclines, scientists have focused their research on anthracycline drugs for the past three decades, discovering or developing various derivatives to achieve optimal efficacy and lower toxicity, resulting in significant progress in drug research. However, further exploration and research into anthracyclines still requires the efforts of many more people. Summary of the Invention
[0004] The inventors unexpectedly discovered that the anthraquinone thiohexacarbazone compound and its metal complex provided in this application have high antitumor activity, low drug resistance, are useful against a variety of drug-resistant tumors, and have low toxicity.
[0005] One objective of this invention is to provide a novel class of metal complexes with anthrayl thiosemicarbazone compounds as ligands, their preparation methods, and their applications in antitumor drugs.
[0006] To achieve the objective of this invention, an anthraylthiohexacarbazone compound, namely ligand P, is provided, the structure of which is shown in Formula I:
[0007] Among them, R 1 The group is selected from H, C1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl; wherein the C1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl groups are optionally substituted by groups independently selected from C1-6 alkyl, C3-10 cycloalkyl and halogens;
[0008] R 2 The group is selected from H, C1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl; wherein the C1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl groups are optionally substituted by groups independently selected from C1-6 alkyl, C3-10 cycloalkyl and halogens;
[0009] R 3 The group is selected from H, C1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl; wherein the C1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl groups are optionally substituted by groups independently selected from C1-6 alkyl, C3-10 cycloalkyl and halogen.
[0010] In one embodiment, the anthraquinone thiohexacarbazone compound has the structure shown in Formula II:
[0011] Where R 1 and R 2 The definition is the same as above.
[0012] In yet another embodiment, the anthraquinone thiohexacarbazone compound has the structure shown in Formula III:
[0013] Where R 1 and R 2 The definition is the same as above.
[0014] In another embodiment, the R in the anthraquinone thiohexacarbazone compound 2 Selected from H, methyl, and ethyl.
[0015] In another embodiment, the R in the anthraquinone thiohexacarbazone compound 2 Selected from ethyl.
[0016] In one specific embodiment, the anthraquinone thiohexacarbazone compound is selected from the following compounds:
[0017] In another aspect, the present invention provides a metal complex having a structure of formula IV: Pm-M-Yn
[0018] Formula IV
[0019] Where M represents a metal ion;
[0020] P is selected from L or LH, where L represents any of the anthraquinone thiocarbazone compounds mentioned above, and LH represents the deprotonated form of any of the anthraquinone thiocarbazone compounds mentioned above.
[0021] Y represents a coligand or counter ion;
[0022] m is selected from 1, 2, or 3; and
[0023] n is selected from 0, 1, 2 or 3.
[0024] In one embodiment, the metal ion M in the metal complex is selected from Cu. 2+ Cu + Ag + Fe 2+ Fe 3+ Co 2+ Co 3+ Zn 2+ Cd 2+ Hg 2+ Ni 2+ Pt 2+ Cr 3+ Mg 2+ Ca 2+ Ba 2+ And Al 3+ .
[0025] In yet another embodiment, the metal ion M in the metal complex is Cu. 2+ or Ni 2+ .
[0026] In another embodiment, the metal ion M in the metal complex is Cu. 2+ .
[0027] In one embodiment, the coligand or counterion Y in the metal complex is selected from NH3, ethylenediamine, pyridine, bipyridine, H2O, CO, ethers, thiourea, triphenylphosphine (PPh3), halide ions, and NO3. - SO4 2- C2O4 2- CN - SCN - N3 - EDTA, acetylacetone, glycine, Na + K + NH4 + ClO4 - PF6 - BF4 - Quaternary ammonium salts and sulfonates.
[0028] In yet another embodiment, the co-ligand or counter ion Y in the metal complex is selected from H, Cl. - SO4 2- BF4 - and ClO4 - .
[0029] In one specific embodiment, the metal complex is selected from metal complexes Ni(LH)2, Cu(LH)Cl, CuL2Cl2, CuL2SO4, CuL2(BF4)2 and CuL2(ClO4)2.
[0030] On the other hand, this application provides a method for preparing the metal complex according to any one of claims 7-13, which includes providing a ligand L and a metal salt MY, and contacting the ligand L and the metal salt MY under conditions suitable for forming the metal complex;
[0031] L, M, and Y have the same definitions as described above.
[0032] On the other hand, this application provides a pharmaceutical composition comprising any of the metal complexes described in the preceding claims, and a pharmaceutically acceptable carrier.
[0033] On another front, this application provides the use of any of the preceding metal complexes in the preparation of medicaments for the prevention and / or treatment of tumors; for example, the tumors are selected from breast cancer, lung cancer, liver cancer, glioma, ovarian cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, endometrial cancer, cervical cancer, squamous cell carcinoma of the head and neck, gallbladder cancer, osteoma, osteosarcoma, thyroid cancer, salivary gland cancer, prostate cancer, thymoma, leukemia, lymphoma, and corresponding drug-resistant tumors. Preferably, the tumors include, but are not limited to, human liver cancer cell line HepG2, human breast cancer cell line MCF-7, and human breast cancer drug-resistant cell lines MCF-7 / ADR, A549 cells, A549 / CDDP cells, etc.
[0034] On the other hand, this application provides the use of the metal complexes described in any of the preceding claims in pharmaceutical remedies for the prevention and / or treatment of tumors; for example, the tumors are selected from breast cancer, lung cancer, liver cancer, glioma, ovarian cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, endometrial cancer, cervical cancer, squamous cell carcinoma of the head and neck, gallbladder cancer, osteoma, osteosarcoma, thyroid cancer, salivary gland cancer, prostate cancer, thymoma, leukemia, lymphoma, and corresponding drug-resistant tumors. Preferably, the tumors include, but are not limited to, human liver cancer cell line HepG2, human breast cancer cell line MCF-7, and human breast cancer drug-resistant cell lines MCF-7 / ADR, A549 cells, A549 / CDDP cells, etc.
[0035] On another front, this application provides a method for preventing and / or treating tumors in a desired individual, comprising applying the metal complex described in any of the preceding claims to the desired individual; for example, the tumor is selected from breast cancer, lung cancer, liver cancer, glioma, ovarian cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, endometrial cancer, cervical cancer, squamous cell carcinoma of the head and neck, gallbladder cancer, osteoma, osteosarcoma, thyroid cancer, salivary gland cancer, prostate cancer, thymoma, leukemia, lymphoma, and corresponding drug-resistant tumors. Preferably, the tumor includes, but is not limited to, human liver cancer cell line HepG2, human breast cancer cell line MCF-7, and human breast cancer drug-resistant cell lines MCF-7 / ADR, A549 cells, A549 / CDDP cells, etc.
[0036] This invention is the first synthesis of anthraylthiohexacarbazone compounds and their metal complexes, and their in vitro and in vivo antitumor activities were investigated. MTT assays showed that the metal complexes provided in this application possess significant antitumor activity. Against drug-resistant cells MCF-7 / ADR with a drug resistance index (DRI) as high as 200 or even higher (DRI 769), Cu(L1)2Cl2, Cu(L2-H)Cl, Cu(L3)2Cl2, and Ni(L1-H)2, Ni(L2-H)2, Ni(L3-H)2 all exhibited antitumor activity comparable to that of sensitive cells, with a drug resistance index of approximately 1.2. Against drug-resistant cells A549 / CDDP, Cu(L1)2SO4 also showed significantly higher antitumor activity than CDDP, with a drug resistance index less than 1.2. Preliminary studies on the antitumor activity mechanism indicate that these metal complexes are not favorable substrates for P-glycoprotein and are not easily expelled from cells by P-glycoprotein. Therefore, they also exhibit good antitumor activity against tumor cells with high expression of P-glycoprotein on their cell membranes, suggesting that these metal complexes may also have a good effect on clinically refractory, multidrug-resistant tumors. In vivo acute toxicity studies in animals showed that the LD50 after intraperitoneal injection... 50 The toxicity is 188.81 mg / kg body weight, which is less than that of traditional drugs such as doxorubicin and cisplatin. Attached Figure Description
[0037] Figure 1 shows the effect of the metal complex Cu(L1)2SO4 on pyroptosis-related proteins.
[0038] Figure 2 shows the changes in body weight of mice 14 days after intraperitoneal injection of different concentrations of Cu(L1)2SO4. * represents p < 0.05; ** represents p < 0.01; *** represents p < 0.001, ns represents p > 0.05, and the significance between each pair of groups was determined by an unpaired two-tailed t-test.
[0039] Figure 3 shows the growth-inhibiting effects of copper complexes with different ligands on A549 cells. Detailed Implementation
[0040] the term
[0041] Anthraylthiocarbazone compounds: These are compounds that form anthraylthiocarbazones by introducing an amino (or amine) thiourea group into the aldehyde (or ketone) site of an anthrayl ring via a condensation reaction, using an anthrayl aldehyde (or anthraquinone) as the parent nucleus. When referring to anthraylthiocarbazone compounds herein, this also includes their stereoisomers, isotopically enriched compounds such as deuterated compounds, solvent compounds, hydrates, and pharmaceutically acceptable salts. In this application, "ligand" and "L" also represent "anthraylthiocarbazone compound," and these terms are interchangeable. When the anthraylthiocarbazone compound in this application acts as a ligand for a metal complex, it can undergo a deprotonated form through mercaptoenol tautomerism. The term "anthraylthiosemicarbazone compound" in this application includes its prototype compound, denoted as L in this application, and its deprotonated form, denoted as LH in this application. In this application, "deprotonation" refers to the removal of the hydrogen ion (H+) from the thiol group in the compound molecule. + ) to break away.
[0042] Metal complexes: Compounds formed by the coordination bonds between a central metal ion (or atom) and ligands. A common example of a metal ion center is Cu. 2+ Cu + Ag + Fe 2+ / Fe 3+ Co 2+ / Co 3+ Zn 2+ Cd 2+ / Hg 2+ Ni 2+ Pt 2+ Cr 3+ Mg 2+ Ca 2+ / Ba 2+ And Al 3+ wait.
[0043] Coligands: In a coordination compound, different types of ligands simultaneously bonded to the central metal ion participate in the construction of the coordination structure. These can include, for example, nitrogen-containing ligands: NH3 (ammonia), ethylenediamine (en), pyridine (C5H5N), bipyridine (bipy); oxygen-containing ligands: H2O (water), CO (carbon monoxide), ethers (R2O); sulfur / phosphorus-containing ligands: thiourea (SC(NH2)2), triphenylphosphine (PPh3); and halide ions: F... - Cl-, Br - I-; Oxyacid anions: NO3 - SO4 2- C2O4 2- (Oxalate); Nitrogen / sulfur anions: CN - (cyanide), SCN - (thiocyanate), N3 - (Azide); aminocarboxylates: EDTA (ethylenediaminetetraacetic acid) and organic bidentate ligands: acetylacetone (acac), glycine (NH2CH2COO) - ).
[0044] Counter ions: Free ions that exist to balance the ionic charge of complexes and typically do not participate in the formation of coordinate bonds. They can include cations such as Na+. + K + NH4 + Anion: ClO4 - PF6 - BF4 - Quaternary ammonium salts: [NR4] + And sulfonate: TsO - .
[0045] The term "substitution," unless otherwise stated, refers to any number of substitutions, such as mono-, di-, tri-, tetra-, or penta-substitutions, if such substitution is permitted. The term "substituted" means that a hydrogen atom is removed and replaced by a substituent.
[0046] Alkyl: The term "alkyl" refers to a straight-chain or branched saturated hydrocarbon group. Alkyl groups can contain about 1 to about 6, about 1 to about 4, or about 1 to about 3 carbon atoms. For example, alkyl groups can contain any number of carbon atoms, such as C1-C2 alkyl, C1-C3 alkyl, C1-C4 alkyl, C1-C5 alkyl, C1-C6 alkyl, C1-C7 alkyl, C1-C8 alkyl, C1-C9 alkyl, C1-C... 10Alkyl, C2-C3 alkyl, C2-C4 alkyl, C2-C5 alkyl, C2-C6 alkyl, C3-C4 alkyl, C3-C5 alkyl, C3-C6 alkyl, C4-C5 alkyl, C4-C6 alkyl, and C5-C6 alkyl. Similarly, in C1-C6 alkyl, C1-C6 refers to the group having 1, 2, 3, 4, 5, or 6 carbon atoms arranged in a straight chain or branched chain. Exemplary alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, and t-butyl), pentyl (e.g., n-pentyl, isopentyl, and neopentyl), and hexyl.
[0047] Cycloalkyl: The term "cycloalkyl" refers to an unsubstituted or substituted non-aromatic carbon ring. Cycloalkyl can include monocyclic or polycyclic (e.g., having 2, 3, or 4 rings) ring systems, including fused rings, spirocyclic rings, and bridged rings (e.g., bridged bicyclic alkyl rings). In some embodiments, the cycloalkyl has about 3 to about 10 carbon atoms, or about 3 to 7 carbon atoms. The cycloalkyl may also have 0, 1, 2, or 3 double bonds and / or 0, 1, or 2 triple bonds. In some embodiments, the cycloalkyl is a C3-C7 monocyclic cycloalkyl.
[0048] Aryl: The term "aryl" or "aromatic group" refers to an unsubstituted or substituted monocyclic or polycyclic aromatic hydrocarbon (e.g., having 2, 3, or 4 fused rings). In some embodiments, the aryl group has about 6 to about 10 carbon atoms. Exemplary aryl groups include, but are not limited to, phenyl, naphthyl, anthracene, phenanthryl, indanyl, and indenyl. Halogen: The term "halogen" refers to fluorine, chlorine, bromine, and iodine.
[0049] Drug-resistant tumors: In this application, "drug-resistant tumors" refers to tumors in which malignant tumor cells develop resistance to originally effective chemotherapy drugs or targeted therapies, resulting in decreased or ineffective treatment effects.
[0050] Example
[0051] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products.
[0052] Example 1: Anthraylthiohexacarbazone compound metal complex and its preparation method
[0053] Preparation of anthraylthiohexacarbazone metal complexes 1-5
[0054] Preparation of ligand L1:
[0055] Dissolve 0.9 g of 4-ethyl-3-thioaminourea in an appropriate amount of methanol, add 1.3 g of 9-anthraaldehyde dissolved in methanol, add 2-3 drops of glacial acetic acid, heat, and react under a protective atmosphere for 6 h. Allow to stand, filter, purify, and dry. The product is ligand L1. Characterization results are as follows: 1 H-NMR (DMSO-d6) δ = 2.502 (t, 3H, CH3), 3.595 (m, 2H, CH2), 7.615 (m, 4H, anthryl), 8.154 (d, 2H, anthryl), 8.386 (t, 1H, NH -C), 8.491 (d, 2H, anthryl), 8.711 (s, 1H, CH=N), 9.274 (s, 1H, anthryl), 11.675 (s, 1H, NH). ESI-MS, m / z (%): 307.62 [M+H] + .
[0056] Preparation of metal complex 1:
[0057] 0.40 g of ligand L1 was dissolved in anhydrous ethanol, and an ethanol solution containing 0.12 g of CuCl2·2H2O was added. The reaction was allowed to proceed for 6 h, followed by filtration, washing, purification, and drying to obtain metal complex 1, namely Cu(L1)2Cl2. The product characterization results were as follows: ESI-MS: m / [CuL1(L1-H)] + 676.83.
[0058] Preparation of metal complex 2:
[0059] Ligand L1 (0.4 g) was dissolved in an appropriate amount of ethanol, and then an ethanol solution containing 0.17 g of CuSO4·5H2O was added. The mixture was reacted at room temperature for 6 h. After filtration, washing, purification, and drying, metal complex 2, Cu(L1)2SO4, was obtained. Product characterization results: ESI-MS: m / z [Cu(L1)2] 2+ 677.32.
[0060] Preparation of metal complex 3:
[0061] Ligand L1 (0.16 g) was dissolved in an appropriate amount of ethanol, and 203 μL of Cu(BF4)2·6H2O aqueous solution was added. The mixture was reacted at room temperature for 6 h, filtered, washed, purified, and dried to obtain metal complex 3, namely Cu(L1)2(BF4)2. The product characterization results are as follows: ESI-MS: m / z [Cu(L1)2] 2+ 677.32.
[0062] Preparation of metal complex 4:
[0063] Ligand L1 (0.4 g) was dissolved in an appropriate amount of ethanol, and then an ethanol solution containing 0.24 g of Cu(ClO4)2 was added. The mixture was reacted at room temperature for 6 hours. After filtration, washing, purification, and drying, metal complex 4, Cu(L1)2(ClO4)2, was obtained. The product characterization results were as follows: ESI-MS: m / z [Cu(L1)2] 2+ 677.07.
[0064] Preparation of metal complex 5:
[0065] Ligand L1 0.40 g was dissolved in an appropriate amount of ethanol, and an ethanol solution containing Ni(Ac)2·4H2O 0.32 g was added dropwise. The mixture was refluxed for 3 h, filtered, washed, purified, and dried to obtain metal complex 5, i.e., Ni(L1-H)2. The product characterization results are as follows: ESI-MS: m / z [Ni(L1-H)2] + 670.77.
[0066] Preparation of anthraylthiohexacarbazone metal complexes 6 and 7
[0067] Preparation of ligand L2:
[0068] Weigh 1g of thioaminourea and 1.9g of 9-anthraaldehyde, dissolve them in an appropriate amount of methanol, add 2-3 drops of glacial acetic acid, react for 6 hours, then stop heating, cool, filter, recrystallize, and dry for 1-2 days to obtain compound L2. 1 H-NMR (300MHz, DMSO-d6)δ=7.58(m,2H,anthryl),7.63(m,2H,anthryl),7.747(s,1H,NH2),8.152(d,J=7.8Hz,2H,anthryl),8.352(s, 1H,NH2),8.57(d,J=8.7Hz,2H,anthryl),8.717(s,1H,CH=N),9.328(s,1H,anthryl),11.668(s,1H,NH).ESI-MS,m / z(%):279.74[M+H] + .EA(%):C 16 H 13 N3S,calcd.:N,15.04;C,68.79;H,4.69;found:N,15.23;C,68.53;H,4.69.
[0069] Preparation of metal complex 6:
[0070] Dissolve 0.60 g of ANS in an appropriate amount of ethanol, then add dropwise an ethanol solution containing 0.19 g of CuCl2·2H2O. React at room temperature for 4 hours, filter, and dry to obtain metal complex 6, namely Cu(L2-H)Cl. The product characterization results are as follows: ESI-MS: m / z [Cu(L2-H)] + 341.81.
[0071] Preparation of metal complex 7:
[0072] Dissolve 0.58 g of ANS in an appropriate amount of ethanol, then add dropwise an ethanol solution containing 0.52 g of Ni(Ac)₂·4H₂O. Reflux for 3 hours, filter, and dry to obtain metal complex 7, namely Ni(L₂-H)₂. The product characterization results are as follows: ESI-MS: m / z [Ni(L₂-H)₂] + 614.88.
[0073] Preparation of anthraylthiohexacarbazone metal complexes 8 and 9
[0074] Preparation of ligand L3:
[0075] Weigh 0.8g of 4-methylthioaminourea and 1.3g of 9-anthraaldehyde, dissolve them in an appropriate amount of methanol, add 2-3 drops of glacial acetic acid, react for 6 hours, cool, filter, recrystallize, and dry to obtain L3. 1 H-NMRRR(300MHz,DMSO-d6)δ=3.024(d,J=10.8Hz,3H,CH3),7.614(m,4H,anthryl),8.156(d,J=7.8Hz,2H,anthryl),8.352(t,1H,N H-C),8.508(d,J=8.7Hz,2H,anthryl),8.749(s,1H,CH=N),9.288(s,1H,anthryl),11.682(s,1H,NH).ESI-MS,m / z(%):293.83[M+H] + .EA(%):C16H13N3S,calcd.:N,14.32;C,69.6;H,5.15;found:N,14.03;C,69.40;H,5.12.
[0076] Preparation of metal complex 8:
[0077] Dissolve 0.5 g of L3 in an appropriate amount of ethanol, then add dropwise an ethanol solution containing 0.15 g of CuCl2·2H2O. React at room temperature for 4 hours. Filter, wash, purify, and dry to obtain metal complex 8, namely Cu(L3)2Cl2. The product characterization results are as follows: ESI-MS: m / z [Cu(L3)2]+ 649.18.
[0078] Preparation of metal complex 9:
[0079] Dissolve 0.5 g of L3 in an appropriate amount of ethanol, then add dropwise an ethanol solution containing 0.4 g of Ni(Ac)2·4H2O. Reflux for 3 h, filter, wash, purify, and dry to obtain metal complex 9, i.e., Ni(L3-H)2. Product characterization results: ESI-MS: m / z [Ni(L3-H)2] + 643.31.
[0080] Preparation of metal complex 12:
[0081] Ligand L3 0.4 g was dissolved in an appropriate amount of ethanol, and then an ethanol solution containing 0.16 g CuSO4·5H2O was added. The mixture was reacted at room temperature for 6 h, filtered, washed, purified, and dried to obtain metal complex 12, i.e., Cu(L3)2SO4. Product characterization results: ESI-MS: m / z [Cu(L3)2] 2+ 649.18.
[0082] The applicant unexpectedly discovered that the metal complex of L1 has better solubility than the metal complex of L3. For example, the metal complex of L1 with copper has better solubility than the metal complex of L3 with copper.
[0083] Preparation of anthraquinone thiohexacarbazone compound metal complex 10
[0084] Preparation of ligand L4:
[0085] Weigh 0.44 g of 2-acetylanthraquinone and 0.3 g of ethylthioaminourea, dissolve them in anhydrous ethanol, add a few drops of glacial acetic acid, and heat under reflux. After 6 h, cool, filter, wash, purify, and dry to obtain ligand L4. 1 H NMR (300MHz, DMSO) δ8.90(s,1H,anthryl),8.84(s,1H,anthtryl),8.65(s,1H,anthryl),8.16(dt,J=9.2,3.4Hz,3H,anthryl),7.93(dd,J=8.9,1. 8Hz,1H,anthryl),7.69–7.54(m,2H,anthtryl),4.36(d,J=5.1Hz,1H,NH-C),3.47–3.41(m,2H,CH2),2.75(s,3H,CH3),1.07(d,J=7.0Hz,3H,CH3).
[0086] Preparation of metal complex 10:
[0087] Weigh 0.2 g of Cu(L4)2 and 0.06 g of copper chloride, dissolve them in anhydrous ethanol, and heat under reflux for 6 h. After the reaction is complete, filter, wash, purify, and dry to obtain metal complex 10, namely Cu(L4)2Cl2. The product characterization results are as follows: ESI-MS: m / z [Cu(L4)2-H] + 704.39.
[0088] Preparation of anthraquinone thiohexacarbazone compound metal complex 11
[0089] Preparation of ligand L5:
[0090] Weigh 0.45g of 9-acetylanthraquinone and 0.26g of ethylthioaminourea, dissolve them separately in anhydrous ethanol, add a few drops of glacial acetic acid, heat under reflux for 6 hours, cool, filter, purify, and dry to obtain ligand L5. 1 H NMR(300MHz,DMSO)δ8.71(s,1H,anthryl),8.20–8.15(m,2H,anthryl),7.89–7.84(m,2H,anthryl),7.63-–7.56(m,4H ,anthryl),4.40(t,J=5.1Hz,1H,NH-C),3.46(qd,J=7.0,5.1Hz,2H,CH2),2.81(s,3H,CH3),1.07(t,J=7.0Hz,3H,CH3).
[0091] Preparation of metal complex 11:
[0092] 0.26 g of L5 and 0.07 g of copper chloride were weighed and dissolved separately in anhydrous ethanol, and the solutions were heated under reflux for 6 h. After the reaction was completed, the solutions were filtered, purified, and dried to obtain metal complex 11, namely Cu(L5)2Cl2. The product characterization results were as follows: ESI-MS: m / z [Cu(L5)2-H] + 704.39.
[0093] Example 2: In vitro antitumor activity analysis of metal complexes 1-6 of anthraylthiohexacarbazone compounds
[0094] 1. Sample preparation: Use DMSO to dissolve metal complexes 1-6 as stock solutions, and dilute with culture medium to the required concentration before use.
[0095] 2. Cell lines: HepG2 cells, MCF-7 cells, MCF-7 / ADR cells, A549 cells, A549 / CDDP cells.
[0096] 3. The MTT assay was used to detect the antitumor cell proliferation effect of metal complexes: Cells in the logarithmic growth phase were collected, centrifuged, the supernatant was discarded, the cells were resuspended in culture medium, counted, and 3 × 10⁶ cells were collected. 3 ~5×10 3 Cells were inoculated into 96-well plates at a concentration of 100 cells / well and cultured for 24 hours to allow complete cell adhesion. Experimental groups were treated with multiple concentrations of drugs (including complexes and positive controls: cisplatin and doxorubicin) and incubated at 37°C with 5% CO2 for 24 hours. The control group was treated with an equal volume of culture medium. Each group had 6 replicates. A negative control group was prepared by adding only cells and no drugs, while a blank control group was prepared by adding only culture medium (with an equal volume of sterile PBS added to the peripheral wells). 24 hours after drug administration, 20 μL of LTT (5 mg / mL) solution was added directly to each well, and the plates were incubated at 37°C for 4 hours. After discarding the supernatant, 100 μL of DMSO was added to each well, and the plates were shaken thoroughly for 10 minutes. The absorbance at 490 nm was measured using a microplate reader, and the results were recorded.
[0097] 4. Cell cycle detection
[0098] Cells in the logarithmic growth phase were routinely digested to prepare a single-cell suspension, with cells spaced at 1×10⁻⁶. 5 Cells were seeded at a concentration of [number] cells / mL in six-well plates. After 24 hours, 4 μM metal complex solution was added and incubated for another 24 hours. This group was designated as the treatment group. The control group was treated with culture medium only. All cells were collected, and approximately 1 × 10 [cells / mL] were [divided / incubated]. 6 Cells were transferred to centrifuge tubes and centrifuged at 1500 rpm for 5 min. After discarding the supernatant, the cells were washed once with PBS solution, leaving approximately 1 mL of PBS in the centrifuge tube. 5 mL of ice-cold 70% ethanol was added and mixed thoroughly for fixation. The mixture was then incubated overnight at 4°C. For detection, the cells were centrifuged to remove the ethanol, washed twice with PBS, and RNase (100 μg / mL) was added. The mixture was incubated at 37°C for 30 min, followed by PI (50 μg / mL) staining solution. Staining was performed at room temperature in the dark for 10 min. 10,000 cells were counted, and the cell cycle phase was detected by flow cytometry. The results were analyzed using cell cycle software.
[0099] 5. Apoptosis detection
[0100] Cells in the logarithmic growth phase were routinely digested to prepare a single-cell suspension, with cells spaced at 1×10⁻⁶. 5 Cells were seeded at a concentration of [number] cells / mL in six-well plates. After 24 hours, the solutions of the respective concentrations of compounds were added and incubated for another 24 hours. All cells were then collected, and the procedure was performed according to the FITC-PI apoptosis kit instructions. The apoptosis rate was detected by flow cytometry, and the results are expressed as the percentage of apoptotic cells.
[0101] result:
[0102] 1. The cytotoxicity MTT assay results showed that metal complexes 1-6 had significant anti-proliferative effects on human hepatocellular carcinoma cells HepG2. The half-maximal inhibitory concentrations (IC50) of metal complexes 1-5, doxorubicin, and cisplatin were compared. 50 As can be seen, the anti-proliferative effects of metal complexes 1-5 on human hepatocellular carcinoma cells HepG2 are roughly equivalent to those of the clinical drug doxorubicin (DOX) (Table 1). Furthermore, metal complexes 10 and 11 also exhibit significant anti-proliferative effects on human breast cancer parental cells MCF-7 (Table 2). This demonstrates that all metal complexes in this application possess significant anti-tumor cell activity.
[0103] Table 1. Half-maximal inhibitory rate (IC50) of metal complexes 1-5 on HepG2 50 (μM)
[0104] Table 2. Half-maximal inhibitory concentrations (IC50) of metal complexes 10 and 11 on MCF-7 50 (μM)
[0105] Furthermore, the IC50 of the metal complexes described in this application on human breast cancer parental cells MCF-7 and doxorubicin-resistant cells MCF-7 / ADR, human non-small cell lung cancer parental cells A549 and cisplatin-resistant cells A549 / CDDP, was also demonstrated. 50 The study found that the metal complexes in this application not only all exhibited significant anti-tumor cell activity, but furthermore, through IC50... 50 The resistance index (DRI) was calculated, and it was found that the DRI values of the metal complexes in this application were all less than 2, indicating that the complexes can effectively overcome drug resistance (Tables 3 and 4).
[0106] Table 3. Half-maximal inhibitory concentration (IC50) of metal complexes on MCF-7 and MCF-7 / ADR 50 (μM) and drug resistance index DRI
[0107] Table 4 shows the half-maximal inhibition (IC50) of the metal complex Cu(L1)2SO4 on A549 and A549 / CDDP. 50 (μM) and drug resistance index DRI
[0108] 2. Cell cycle experiments showed that the complex Cu(L1)2Cl2 had a certain effect on the cell cycle. After treatment with the copper(II) complex Cu(L1)2Cl2, compared with the control group, the number of G0 / G1 cells in MCF-7 cells decreased, the number of S-phase cells was almost unaffected, and the number of G2 / M cells increased significantly. MCF-7 / ADR cells showed a similar trend, with a decrease in G0 / G1 cells, almost no effect on S-phase cells, and a significant increase in G2 / M-phase cells (Table 5).
[0109] Table 5 Effects of Cu(L1)2Cl2 on the cell cycle of MCF-7 and MCF-7 / ADR cells.
[0110] 3. The results of the apoptosis experiment showed that, within the tested concentration and time range of the complex, the apoptosis rates of MCF-7 cells and MCF-7 / ADR cells treated with the copper complex Cu(L1)2Cl2 6μM for 24h were 10.5% and 6.7%, respectively.
[0111] Example 3: Antitumor activity of metal complexes of anthracycline aminothiourea compounds in mice
[0112] MCF-7 tumor cells were cryopreserved and revived using liquid nitrogen and inoculated into well-grown tumor nodules in Balb / c nude mice (SPF grade). The tumor cells were then prepared into a single-cell suspension using a tissue homogenizer, and 7 × 10⁶ cells were subcutaneously injected into the right anterior axilla of each mouse. 6 Cells were randomly divided into four groups of eight cells each. The four groups were: a tumor model control group; a positive control group (cisplatin 4 mg / kg body weight, intraperitoneal injection 4 times, every 3 days); a high-dose group (15 mg / kg body weight, intraperitoneal injection 12 times) of Cu(L1)2Cl2 once daily; and a low-dose group (5 mg / kg body weight, intraperitoneal injection 12 times) of Cu(L1)2Cl2 once daily. The administration time for each group was from the time of tumor inoculation until the average tumor volume reached approximately 140 mm². 3 The experiment began on day 8 after tumor cell inoculation and lasted for a total of 20 days. Approximately 24 hours after the last administration, animals were sacrificed, weighed, and the tumor was completely dissected and weighed again to calculate the tumor inhibition rate. The results were statistically analyzed using Microsoft Excel. The entire experiment was conducted in an animal housing room equipped with a barrier system. The housing temperature was 20–25℃, with a daily temperature difference ≤3℃, relative humidity 40–60%, 12-hour light / dark cycle, air cleanliness level 100, and ammonia concentration ≤14 mg / m³. 3 Noise level ≤ 60 dB, working illuminance 150-300 LX, animal illuminance 100-200 LX.
[0113] Cu(L1)2Cl2 has an inhibitory effect on human transplantable breast cancer MCF-7. The high-dose group (15 mg / kg body weight / time, once a day) has an inhibition rate of 51.66%, the low-dose group (5 mg / kg body weight / time, once a day) has an inhibition rate of 14.20%, and the positive control drug cisplatin (4 mg / kg body weight, once every 3 days) has an inhibition rate of 61.63%.
[0114] Example 4. In vitro cytotoxicity analysis of metal complexes of anthracycline aminothiourea compounds
[0115] 1. Sample preparation: Dissolve the metal complex in DMSO as a stock solution, and dilute it with culture medium to the required concentration before use.
[0116] 2. Cell lines: HUVEC cells and H9C2 cells.
[0117] 3. The effects of metal complexes Cu(L1)2Cl2 and Cu(L1)2SO4 on the proliferation of endothelial cells and cardiomyocytes were detected using the MTT assay: Cells in the logarithmic growth phase were collected, centrifuged, the supernatant was discarded, the cells were resuspended in culture medium, counted, and 1×10⁻⁶ cells were collected. 4 Cells were inoculated into 96-well plates at concentrations of 0, 0.01, 0.1, 1, 5, 10, 15, and 20 μg / mL, respectively, and cultured at 37°C and 5% CO2 for 24, 48, and 72 hours, respectively. The control group received an equal volume of culture medium. Each group had six replicates. A negative control group (cells only, no drug) and a blank control group (culture medium only, no cells) served as the blank control. 24 hours after drug administration, 20 μL of MTT (5 mg / mL) solution was added directly to each well, and the plates were incubated at 37°C for 4 hours. After discarding the supernatant, 100 μL of DMSO was added to each well, and the plates were shaken thoroughly for 10 minutes. The absorbance at 490 nm was measured using a microplate reader, and the results were recorded (Table 6).
[0118] Table 6. Half-maximal inhibitory rate (IC50) of metal complexes on HUVEC and H9C2 cells 50 (μM)
[0119] HUVEC human umbilical vein endothelial cells are primary cells isolated from the umbilical vein of newborns. H9C2 cells are a rat cardiomyocyte cell line derived from the heart tissue of BD1X rats during embryonic development. HUVEC and H9C2 cells are classic cell models widely used in vascular biology research, commonly used in cardiovascular disease studies (such as myocardial ischemia and hypoxic injury) and drug cardiotoxicity assessment. The IC50 values of different cell lines after 72 hours of incubation with Cu(L1)2SO4 were compared. 50Values: HepG2 cells were 0.43±0.03μM, MCF-7 cells were 1.76±0.25μM, and A549 cells were 1.26±0.20μM. Compared with these tumor cells, after incubation with Cu(L1)2SO4 for 72 h, the IC50 values of HUVEC and H9C2 cells were significantly lower. 50 The values were all higher than the IC50 of tumor cells. 50 The values indicate that Cu(L1)2SO4 has a relatively small inhibitory effect on the proliferation of healthy cells, which is beneficial for reducing the toxic effects of chemotherapy drugs on normal tissues. The results are shown in Table 7.
[0120] Table 7. Half-maximal inhibitory rate (IC50) of the metal complex Cu(L1)2SO4 on MCF-7 cells 50 (μM)
[0121] 4. Detection of apoptosis and pyroptosis
[0122] Cells in the logarithmic growth phase were routinely digested to prepare a single-cell suspension, and the cells were spaced at 2 × 10⁻⁶ cells per cell line. 5 Cells were seeded at a concentration of [number] cells / well in six-well plates. After 24 hours, a compound solution at a concentration of 2 μg / mL was added and incubated for another 24 hours. All cells were then collected, and the FITC-PI apoptosis kit was administered according to the manufacturer's instructions. The apoptosis rate was detected by flow cytometry, and the results are expressed as the percentage of apoptotic cells (see Table 8).
[0123] Table 8. Apoptosis rate of A549 and A549 / CDDP cells treated with the metal complex Cu(L1)2SO4.
[0124] The apoptosis assay results showed that, within the tested concentration and time range of the complex, the apoptosis rate of A549 cells treated with the copper complex Cu(L1)2SO4 2 μg / mL for 24 h was 31.2%. In contrast, the double-positive detection rate of drug-resistant A549 / CDDP cells treated with Cu(L1)2SO4 2 μg / mL for 24 h was 25.2%, and further analysis indicated that pyroptosis was the predominant mode of cell death.
[0125] 5. Analysis of pyrolysis
[0126] Protein extraction: Culture dishes seeded with A549 cells and 549 / DDP cells were randomly divided into a control group and a Cu(L1)2SO4 group. 1 mL of complete culture medium containing 2 μg / mL of the compound was added to the Cu(L1)2SO4 group. The culture dishes were incubated for 24 hours to allow the compound to fully act on the cells. After 24 hours, the culture medium was discarded, and the cells were washed with pre-chilled PBS (containing 1 mM PMSF). 150-250 μL of pre-chilled RIPA lysis buffer (containing 1 mM PMSF) was added to each dish and the cells were lysed on ice. After lysis, the lysate was transferred to 1.5 mL centrifuge tubes and centrifuged at 4°C and 12000 rpm for 15 min. The supernatant was collected and SDS-PAGE loading buffer was added at a 4:1 ratio. After mixing, the protein was denatured by incubating at 95°C for 10 min. The cells were then aliquoted, labeled, and stored at -80°C for later use.
[0127] Protein quantification: Mix 2 μL of undenatured protein supernatant with 18 μL of standard dilution in a 96-well plate, and add a series of protein standard solutions ranging from 0-0.5 mg / mL. Prepare working solutions by mixing BCA reagents A and B at a 50:1 ratio, and add 200 μL to each well. Incubate at 37°C for 30 min, and measure the absorbance of each well at 570 nm using a microplate reader. Calculate the protein concentration in the sample based on the standard curve.
[0128] Protein electrophoresis: Before the experiment, clean and dry all necessary equipment. Prepare 1× electrophoresis buffer (room temperature) and transfer buffer (store at 4℃). Load the gel into the electrophoresis tank, add the sample and marker, and electrophores at 80V for 30 minutes. After the sample enters the separating gel, adjust the voltage to 120V until bromophenol blue migrates to the bottom of the gel. After electrophoresis, assemble the gel and PVDF membrane into a sandwich structure in the following order: positive electrode-sponge-filter paper-membrane-gel-filter paper-sponge-negative electrode. Place the sandwich in a transfer apparatus (with a pre-set ice box) and calculate the transfer time at 100V and 1kD / min. After transfer, wash the PVDF membrane with 1×TBST for 5 minutes, immerse it in blocking buffer, and block it on a shaker at room temperature for 1 hour (20 rpm). Wash three times with 1×TBST, then incubate with diluted primary antibody at 4℃ for 12 hours (50 rpm). Wash three times with 1×TBST, then incubate with diluted secondary antibody at room temperature for 2 hours. Wash three more times with 1×TBST and perform protein detection and analysis.
[0129] Protein development: Prepare the ECL chemiluminescence developing working solution according to the ratio of solution A to solution B = 1:1. Add the working solution to the washed PVDF membrane, time for 1 minute, then blot off the excess liquid with filter paper and perform detection using a chemiluminescence developer.
[0130] The results are shown in Figure 1. Analysis of pyroptosis-related protein expression levels: After Cu(L1)2SO4 treatment, the level of Cleaved-Caspase-3 increased in A549 cells, but this did not cause changes in the expression levels of GSDME and its N-terminal fragment GSDME-N, indicating that Cu(L1)2SO4 treatment did not induce pyroptosis in A549 cells, but rather apoptosis was the predominant mode. However, in A549 / DDP cells treated with Cu(L1)2SO4, the expression levels of pyroptosis-related proteins Caspase-3 and its activated form Cleaved-Caspase-3, as well as GSDME and its N-terminal fragment GSDME-N, were significantly upregulated, indicating that Cu(L1)2SO4 induces pyroptosis in A549 / DDP cells by activating the Caspase-3 pathway.
[0131] Example 5: Intra-intensive toxicity analysis of metal complexes of anthracycline aminothiourea compounds
[0132] 1. In vivo acute toxicity analysis of the metal complex Cu(L1)2Cl2
[0133] Kunming mice weighing 18–22g, SPF grade, were used in the experiment. The entire experiment was conducted in a barrier-controlled animal housing. The housing temperature was 20–25℃, with a daily temperature difference ≤3℃, relative humidity 40–60%, 12-hour light and dark alternation, air cleanliness level 100, and ammonia concentration ≤14mg / m³. 3 Noise level ≤ 60 dB, working illuminance 150-300 LX, animal illuminance 100-200 LX.
[0134] Weigh out Cu(L1)2Cl2 powder using a balance and place it in a sterile vial. Add a small amount of DMSO to dissolve and shake well. Then add sterile 0.9% sodium chloride injection to dilute and prepare a suspension. The final concentration of DMSO is 2.5%.
[0135] 1) After the preliminary experiment, 24 mice were randomly divided into 4 groups of 6 mice each, with half males and half females.
[0136] 2) Based on the preliminary experiment, the minimum dose was set at 128.0 mg / kg body weight, and the maximum dose at 250 mg / kg, arranged in a geometric progression with a step difference (K) of 0.80. The drug was diluted in decreasing increments. Animals were weighed, and the dosage was calculated based on body weight. Each rat was administered the drug via intraperitoneal injection once, at a dose of 0.2 mL / 10 g body weight. Animals were observed for two weeks after administration, and their appearance, activity, and mortality were recorded. The median lethal dose (LD50) was calculated using Bliss's method. 50 )value.
[0137] Intraperitoneal injection of Cu(L1)2Cl2 resulted in decreased activity in the animals. Although the number of animals exhibiting abnormal reactions increased with increasing dosage, they generally returned to normal within 3-4 days. No abnormalities were observed in urination, defecation, or fur, and weight increased. Mice began dying 24 hours after administration; the number of deaths and the time of death increased and accelerated with increasing dosage. Post-mortem examination revealed no significant abnormalities in the major organs. The experimental results are shown in Tables 9 and 10.
[0138] LD50 of intraperitoneal injection 50 The LD50 of Cu(L1)2Cl2 in male and female mice was 188.81 mg / kg body weight, with a 95% confidence limit of 142.65–292.89 mg / kg body weight. 50 No statistical difference.
[0139] Table 9. Acute toxicity results and LD50 of Cu(L1)2Cl2 powder. 50 calculate
[0140] The regression equation is y(Probit) = -9.8302 + 6.5158Log(D).
[0141] Median lethal dose (LD50) 50 =188.81mg / kg
[0142] LD 50 (Feiller corrected) 95% confidence limit = 142.65 - 292.89 mg / kg LD5 = 105.58 mg / kg
[0143] LD 95 = 337.66 mg / kg
[0144] Table 10 Time of death in animals after intraperitoneal injection of Cu(L1)2Cl2
[0145] 2. In vivo acute toxicity analysis of the metal complex Cu(L1)2SO4
[0146] The acute toxicity was evaluated using Balb / c mice (half male and half female). Cu(L1)2SO4 was administered via intraperitoneal injection at gradient doses (100–500 mg / kg), with 5% DMSO saline as a negative control. During the 14-day observation period, body weight changes and mortality were dynamically monitored to comprehensively assess systemic toxicity. Body weight statistics within 14 days after administration (Figure 2) showed no significant differences in body weight changes among all dose groups (including the highest dose of 500 mg / kg). No significant dose-dependent weight loss or growth inhibition was observed, indicating that Cu(L1)2SO4 did not induce significant metabolic disturbances or systemic toxicity within the experimental dose range. No animals died within 14 days in any experimental group, indicating that its median lethal dose (LD50) exceeded 500 mg / kg, significantly superior to the clinically commonly used drug cisplatin (LD50). 50 =15.2mg / kg), doxorubicin (LD50) 50 =15.3 mg / kg), further confirming that Cu(L1)2SO4 has an extremely low risk of acute toxicity.
[0147] Example 6: Comparison of cytotoxicity of metal complexes of anthraquinone thiohexacarbazone compounds
[0148] 1. Experimental Methods
[0149] The toxicity of Cu(L3)2SO4 and Cu(L1)2SO4 to A549 cells was assessed using the MTT assay. Cells were seeded into 96-well plates, and after adhesion, the medium was replaced with different concentrations of the drug. After incubation for 24, 48, and 72 hours, the drug solution was discarded, and the cells were washed with PBS to remove residual drug. 100 μL of fresh medium and 20 μL of MTT solution (5 mg / mL) were added to each well, and the cells were cultured for another 4 hours. The medium was then discarded, and DMSO was added to dissolve and crystallize the cells. The absorbance at 490 nm was measured using a microplate reader. Cell viability was calculated as ((OD value of the drug-treated group - OD value of the blank group) / ((OD value of the control group - OD value of the blank group)) × 100%. IC50 was calculated. 50 value.
[0150] 2. Results Analysis:
[0151] The experimental results showed that both copper complexes exhibited strong cytotoxic effects on A549 cells. Treatment of A549 cells with different concentrations of copper complexes resulted in a significant concentration-dependent inhibition of cell growth. Cell viability gradually decreased with increasing copper complex concentration. The inhibitory effects showed similar trends at 24h, 48h, and 72h, with the high-concentration group showing the most significant inhibitory effect on cell growth (Figure 3).
[0152] Table 11 shows the cell half-maximal inhibition rate (IC50) of Cu(L3)2SO4 at 24h, 48h, and 72h. 50The values were 10.08±1.19, 7.03±0.60, and 3.61±0.80 μM, respectively; the IC50 values of Cu(ENS)2SO4 at 24h, 48h, and 72h were... 50 The values were 4.39±0.78, 1.36±0.31, and 0.75±0.10 μM, respectively. In comparison, Cu(L1)2SO4 showed stronger anti-tumor proliferation ability.
[0153] Table 11. Half-maximal inhibitory concentration (ICP-C) of metal complexes on A549 cells at different time points (μM)
[0154] Although the present invention has been described in detail above with general descriptions and specific embodiments, modifications or improvements can be made to it, which will be obvious to those skilled in the art. Therefore, all such modifications or improvements made without departing from the spirit of the present invention fall within the scope of protection claimed by the present invention.
Claims
1. An anthracenyl thiosemicarbazone compound having the structure shown in Formula I: ###00001### Formula I wherein R 1 H, C1-6alkyl, C3-10cycloalkyl, and C6-10aryl; wherein said C1-6alkyl, C3-10cycloalkyl, and C6-10aryl are optionally substituted with groups independently selected from C1-6alkyl, C3-10cycloalkyl, and halo; R 2 H, C1-6alkyl, C3-10cycloalkyl, and C6-10aryl; wherein said C1-6alkyl, C3-10cycloalkyl, and C6-10aryl are optionally substituted with groups independently selected from C1-6alkyl, C3-10cycloalkyl, and halo; R 3 selected from H, C1-6alkyl, C3-10cycloalkyl, and C6-10aryl; wherein said C1-6alkyl, C3-10cycloalkyl, and C6-10aryl are optionally substituted with groups independently selected from C1-6alkyl, C3-10cycloalkyl, and halo.
2. The compound of claim 1 having the structure of Formula II: wherein R 1 and R 2 are as defined in claim 1.
3. The compound of claim 1 having the structure of formula III: ###00003### III wherein R 1 and R 2 are as defined in claim 1.
4. The compound according to any one of claims 1-3, wherein R 2 is selected from H, methyl and ethyl.
5. The compound according to any one of claims 1-4, wherein said R 2 is selected from ethyl.
6. The compound according to any one of claims 1-5, selected from:
7. A metal complex having a structure of formula IV: Pm-M-Yn, Formula IV wherein M represents a metal ion; P is selected from L or LH, where L represents the anthraquinone thiocarbazone compound according to any one of claims 1-6, and LH represents the deprotonated form of the anthraquinone thiocarbazone compound according to any one of claims 1-6. Y represents a coligand or counter ion; m is selected from 1, 2, or 3; and n is selected from 0, 1, 2 or 3.
8. The metal complex according to claim 7, wherein the metal ion M is selected from Cu. 2+ Cu + Ag + Fe 2+ Fe 3+ Co 2+ Co 3+ Zn 2+ Cd 2+ Hg 2+ Ni 2+ Pt 2+ Cr 3+ Mg 2+ Ca 2+ Ba 2+ And Al 3+ .
9. Metal complex according to any one of claims 7 or 8, wherein the metal ion M is Cu 2+ or Ni 2+ .
10. Metal complex according to any one of claims 7 to 9, wherein the metal ion M is Cu 2+ .
11. The metal complex according to any one of claims 7-10, wherein the coligand or counterion Y is selected from NH3, ethylenediamine, pyridine, bipyridine, H2O, CO, ethers, thiourea, triphenylphosphine (PPh3), halide ions, NO3. - SO4 2- C2O4 2- CN - SCN - N3 - EDTA, acetylacetone, glycine, Na + K + NH4 + ClO4 - PF6 - BF4 - Quaternary ammonium salts and sulfonates.
12. Metal complex according to any one of claims 7-11, wherein the co-ligand or counterion Y is selected from the group consisting of H, CI - , SO4 2- , BF4 - , and CI04 - , for example Y is selected from SO4 2- .
13. The metal complex according to any one of claims 7-12, wherein the metal complex is selected from metal complexes Ni(LH)2, Cu(LH)Cl, CuL2Cl2, CuL2SO4, CuL2(BF4)2 and CuL2(ClO4)2, for example CuL2SO4.
14. A method for preparing the metal complex according to any one of claims 7-13, comprising providing a ligand L and a metal salt MY, and contacting the ligand L and the metal salt MY under conditions suitable for forming the metal complex; L, M, and Y have the same definitions as in claim 1.
15. A pharmaceutical composition comprising the metal complex of any one of claims 7-13, and a pharmaceutically acceptable carrier.
16. Use of the metal complex according to any one of claims 7-13 in the preparation of a medicament for the prevention and / or treatment of tumors; for example, the tumors are selected from breast cancer, lung cancer, liver cancer, glioma, ovarian cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, endometrial cancer, cervical cancer, squamous cell carcinoma of the head and neck, gallbladder cancer, osteoma, osteosarcoma, thyroid cancer, salivary gland cancer, prostate cancer, thymoma, leukemia, and lymphoma, for example, the tumors are drug-resistant.
